Can Diffusion Tensor Imaging Noninvasively Detect IDH1 Gene Mutations in Astrogliomas? A Retrospective Study of 112 Cases

REFERENCES

1. 1.↵
   1. Parsons DW,
   2. Jones S,
   3. Zhang X,
   4. et al

   . An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807–12

   Abstract/FREE Full Text
2. 2.↵
   1. Yan H,
   2. Parsons DW,
   3. Jin G,
   4. et al

   . IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Nikiforova MN,
   2. Hamilton RL

   . Molecular diagnostics of gliomas. Arch Pathol Lab Med 2011;135:558–68

   PubMed
4. 4.↵
   1. Horbinski C,
   2. Kofler J,
   3. Kelly LM,
   4. et al

   . Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. J Neuropathol Exp Neurol 2009;68:1319–25

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Capper D,
   2. Sahm F,
   3. Hartmann C,
   4. et al

   . Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am J Surg Pathol 2010;34:1199–204

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Juratli TA,
   2. Kirsch M,
   3. Robel K,
   4. et al

   . IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. NeuroOncol 2012;108:403–10

   CrossRef
7. 7.↵
   1. SongTao Q,
   2. Lei Y,
   3. Si G,
   4. et al

   . IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 2012;103:269–73

   CrossRefPubMed
8. 8.↵
   1. Loussouarn D,
   2. Le Loupp AG,
   3. Frenel JS,
   4. et al

   . Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int J Oncol 2012;40:2058–62

   PubMed
9. 9.↵
   1. Metellus P,
   2. Coulibaly B,
   3. Colin C,
   4. et al

   . Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010;120:719–29

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Dang L,
    2. White DW,
    3. Gross S,
    4. et al

    . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739–44

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Ward PS,
    2. Patel J,
    3. Wise DR,
    4. et al

    . The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010;17:225–34

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Capper D,
    2. Simon M,
    3. Langhans CD,
    4. et al

    . 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer 2012;131:766–68

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Choi C,
    2. Ganji SK,
    3. DeBerardinis RJ,
    4. et al

    . 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 2012;18:624–29

    CrossRefPubMed
14. 14.↵
    1. Pope WB,
    2. Prins RM,
    3. Albert Thomas M,
    4. et al

    . Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J NeuroOncol 2012;107:197–205

    CrossRefPubMed
15. 15.↵
    1. Khayal IS,
    2. Vandenberg SR,
    3. Smith KJ,
    4. et al

    . MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. NeuroOncol 2011;13:1192–201

    Abstract/FREE Full Text
16. 16.↵
    1. Louis DN,
    2. Ohgaki H,
    3. Wiestler OD,
    4. et al

    . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Takano S,
    2. Tian W,
    3. Matsuda M,
    4. et al

    . Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 2011;28:115–23

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Khalid L,
    2. Carone M,
    3. Dumrongpisutikul N,
    4. et al

    . Imaging characteristics of oligodendrogliomas that predict grade. AJNR Am J Neuroradiol 2012;33:852–57

    Abstract/FREE Full Text
19. 19.↵
    1. Brander A,
    2. Kataja A,
    3. Saastamoinen A,
    4. et al

    . Diffusion tensor imaging of the brain in a healthy adult population: normative values and measurement reproducibility at 3 T and 1.5 T. Acta Radiol 2010;51:800–07

    Abstract/FREE Full Text
20. 20.↵
    1. Nutt CL,
    2. Mani DR,
    3. Betensky RA,
    4. et al

    . Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602–07

    Abstract/FREE Full Text
21. 21.↵
    1. Le Bihan D

    . Looking into the functional architecture of the brain with diffusion MRI. Nat Rev Neurosci 2003;4:469–80

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Jenkinson MD,
    2. Smith TS,
    3. Brodbelt AR,
    4. et al

    . Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. J Magn Reson Imaging 2007;26:1405–12

    CrossRefPubMed
23. 23.↵
    1. Beppu T,
    2. Inoue T,
    3. Shibata Y,
    4. et al

    . Measurement of fractional anisotropy using diffusion tensor MRI in supratentorial astrocytic tumors. J NeuroOncol 2003;63:109–16

    CrossRefPubMed
24. 24.↵
    1. Mikkelsen T

    . Predicting survival in glioblastomas using diffusion tensor imaging metrics. J Magn Reson Imaging 2010;32:788–95

    CrossRefPubMed
25. 25.↵
    1. Zhao S,
    2. Lin Y,
    3. Xu W,
    4. et al

    . Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009;324:261–65

    Abstract/FREE Full Text
26. 26.↵
    1. Liu Y,
    2. Jiang W,
    3. Liu J,
    4. et al

    . IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma. J Neurooncol 2012;109:253–60

    CrossRefPubMed
27. 27.↵
    1. Graham DI,
    2. Lantos PL

    . Greenfield's Neuropathology. London: Hodder Arnold Publisher; 2002:767–1052
28. 28.↵
    1. Jolapara M,
    2. Patro SN,
    3. Kesavadas C,
    4. et al

    . Can diffusion tensor metrics help in preoperative grading of diffusely infiltrating astrocytomas? A retrospective study of 36 cases. Neuroradiology 2011;53:63–68

    CrossRefPubMed
29. 29.↵
    1. Byrnes TJ,
    2. Barrick TR,
    3. Bell BA,
    4. et al

    . Diffusion tensor imaging discriminates between glioblastoma and cerebral metastases in vivo. NMR Biomed. 2011;24:54–60

    CrossRefPubMed
30. 30.↵
    1. Jakab A,
    2. Molnár P,
    3. Emri M,
    4. et al

    . Glioma grade assessment by using histogram analysis of diffusion tensor imaging-derived maps. Neuroradiology 2011;53:483–91

    CrossRefPubMedWeb of Science
31. 31.↵
    1. Zou QG,
    2. Xu HB,
    3. Liu F,
    4. et al

    . In the assessment of supratentorial glioma grade: the combined role of multivoxel proton MR spectroscopy and diffusion tensor imaging. Clin Radiol 2011;66:953–60

    CrossRefPubMed
32. 32.↵
    1. Gupta R,
    2. Webb-Myers R,
    3. Flanagan S,
    4. et al

    . Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. J Clin Pathol 2011;64:835–44

    Abstract/FREE Full Text
33. 33.↵
    1. Capper D,
    2. Weissert S,
    3. Balss J,
    4. et al

    . Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010;20:245–54

    CrossRefPubMedWeb of Science
34. 34.↵
    1. Hartmann C,
    2. Meyer J,
    3. Balss J,
    4. et al

    . Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009;118:469–74

    CrossRefPubMedWeb of Science